公开(公告)号：US20230125280A1

公开(公告)日：2023-04-27

申请号：US17944060

申请日：2022-09-13

申请人： Cytokinetics, Incorporated

发明人： Ippei SATO ,  Takashi KAMIKUBO ,  Masanori MIURA ,  Yuji MATSUSHIMA ,  Hiroaki TANAKA ,  Yasuhiro SHIINA ,  Susumu YAMAKI ,  Tomoyuki SAITO ,  Hiroshi KIYOHARA ,  Munemichi OHE ,  Kayoko MIHARA ,  Bradley Paul MORGAN ,  Fady MALIK ,  Scott Emile COLLIBEE ,  Luke ASHCRAFT ,  Pu-Ping LU ,  Jeffrey Michael WARRINGTON ,  Marc GARARD

IPC分类号： C07D491/20 ,  C07D491/107 ,  C07D217/24 ,  C07D471/04 ,  C07D217/26 ,  C07D471/10 ,  A61P21/00

摘要： Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

公开(公告)号：US20200270266A1

公开(公告)日：2020-08-27

申请号：US16871532

申请日：2020-05-11

申请人： Astellas Pharma Inc. ,  Cytokinetics, Incorporated

发明人： Ippei SATO ,  Takashi KAMIKUBO ,  Masanori MIURA ,  Yuji MATSUSHIMA ,  Hiroaki TANAKA ,  Yasuhiro SHIINA ,  Susumu YAMAKI ,  Tomoyuki SAITO ,  Hiroshi KIYOHARA ,  Munemichi OHE ,  Kayoko MIHARA ,  Bradley Paul MORGAN ,  Fady MALIK ,  Scott Emile COLLIBEE ,  Luke ASHCRAFT ,  Pu-Ping LU ,  Jeffrey Michael WARRINGTON ,  Marc GARARD

IPC分类号： C07D491/20 ,  C07D491/107 ,  C07D217/24 ,  C07D471/04 ,  C07D217/26 ,  C07D471/10 ,  A61P21/00

摘要： Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

公开(公告)号：US20170233402A1

公开(公告)日：2017-08-17

申请号：US15429738

申请日：2017-02-10

申请人： Astellas Pharma Inc. ,  Cytokinetics, Incorporated

发明人： Ippei SATO ,  Takashi KAMIKUBO ,  Masanori MIURA ,  Yuji MATSUSHIMA ,  Hiroaki TANAKA ,  Yasuhiro SHllNA ,  Susumu YAMAKI ,  Tomoyuki SAITO ,  Hiroshi KIYOHARA ,  Munemichi OHE ,  Kayoko MIHARA ,  Bradley Paul MORGAN ,  Fady MALIK ,  Scott Emile COLLIBEE ,  Luke ASHCRAFT ,  Pu-Ping LU ,  Jeffrey Michael WARRINGTON ,  Marc GARARD

IPC分类号： C07D491/20 ,  C07D471/10 ,  C07D471/04 ,  C07D217/26 ,  C07D491/107 ,  C07D217/24

CPC分类号： C07D491/20 ,  C07D217/24 ,  C07D217/26 ,  C07D471/04 ,  C07D471/10 ,  C07D491/107

摘要： Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.